VLS Valneva SE

VALNEVA - Declaration of shares and voting rights: December 31, 2022

VALNEVA - Declaration of shares and voting rights: December 31, 2022

VALNEVA

Declaration of shares and voting rights

December 31, 2022

__________________________________________________________________________________________

  

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment A

Declaration date: January 5, 2023

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the changeDate on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



 



 



 138,367,482



ordinary shares with a par value of €0.15 each
160,954,396Exercise of 12,500 BSA equity warrant



 



Double voting rights granted on 9,775 ordinary shares



 



Buyback of 20,514 preferred shares convertible into ordinary shares, with a par value of €0.15 each
December 1st, 8 & 10, 2022

  



December 7, 9, 16 & 23, 2022



 



December 27, 2022 i

160,809,560

i Management Board decisions of November 28, 2022. Clearance and settlement on December 27, 2022.

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
05/01/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
 PRESS RELEASE

Valneva meldet vorläufige ungeprüfte Umsätze und liquide Mittel für 20...

Valneva meldet vorläufige ungeprüfte Umsätze und liquide Mittel für 2025; gibt einen Ausblick für 2026 Gesamtumsatz von 174,7 Millionen Euro im Rahmen der Prognose, davon 157,9 Millionen Euro aus Produktumsatz Starke Liquiditätsposition zum Jahresende in Höhe von 109,7 Millionen Euro, mit verbesserter finanzieller Flexibilität nach erfolgreicher Umschuldung  2026 könnte ein Jahr des Wandels werden, da in der ersten Jahreshälfte Daten zur Phase 3 der Lyme-Borreliose-Studie erwartet werden Der Vertrag des Chief Executive Officers wurde um weitere drei Jahre verlängert, wodurch die Kontinuität...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch